Zacks: Brokerages Expect OraSure Technologies, Inc. (OSUR) Will Announce Earnings of -$0.06 Per Share

Wall Street analysts expect OraSure Technologies, Inc. (NASDAQ:OSUR) to announce earnings per share (EPS) of ($0.06) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for OraSure Technologies’ earnings. OraSure Technologies posted earnings of $0.21 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 128.6%. The business is scheduled to announce its next quarterly earnings results on Wednesday, May 2nd.

According to Zacks, analysts expect that OraSure Technologies will report full year earnings of $0.29 per share for the current year, with EPS estimates ranging from $0.24 to $0.35. For the next fiscal year, analysts expect that the company will post earnings of $0.51 per share, with EPS estimates ranging from $0.49 to $0.52. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for OraSure Technologies.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The company had revenue of $52.00 million during the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. OraSure Technologies’s revenue was up 46.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 EPS.

OSUR has been the subject of several analyst reports. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a report on Friday, February 9th. Canaccord Genuity reiterated a “buy” rating and issued a $24.00 price target on shares of OraSure Technologies in a report on Friday, February 2nd. BidaskClub upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Jefferies Group reiterated a “buy” rating and issued a $23.00 price target on shares of OraSure Technologies in a report on Friday, October 20th. Finally, ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $22.25.

Several hedge funds have recently added to or reduced their stakes in the company. Oppenheimer Asset Management Inc. purchased a new stake in OraSure Technologies during the 3rd quarter worth $186,000. Shikiar Asset Management Inc. purchased a new stake in OraSure Technologies during the 4th quarter worth $207,000. Piedmont Investment Advisors LLC purchased a new stake in OraSure Technologies during the 2nd quarter worth $216,000. Koch Industries Inc. purchased a new stake in OraSure Technologies during the 2nd quarter worth $216,000. Finally, ARP Americas LLC purchased a new stake in OraSure Technologies during the 3rd quarter worth $221,000. Institutional investors and hedge funds own 91.62% of the company’s stock.

Shares of OraSure Technologies (NASDAQ:OSUR) traded up $0.15 on Thursday, reaching $18.01. The company’s stock had a trading volume of 532,792 shares, compared to its average volume of 735,487. The firm has a market cap of $1,048.00, a P/E ratio of 35.31, a PEG ratio of 4.82 and a beta of 1.43. OraSure Technologies has a 52 week low of $10.70 and a 52 week high of $23.01.

TRADEMARK VIOLATION NOTICE: This piece was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://stocknewstimes.com/2018/02/15/zacks-brokerages-expect-orasure-technologies-inc-osur-will-announce-earnings-of-0-06-per-share.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get a free copy of the Zacks research report on OraSure Technologies (OSUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply